ClinicalTrials.Veeva

Menu

The Effect of Related Blood Markers on Diabetic Peripheral Neuropathy

W

Wenzhou Medical University

Status and phase

Enrolling
Phase 4

Conditions

Diabetic Peripheral Neuropathy

Treatments

Drug: hypoglycemic Agents(metformin)
Drug: lipid-lowering drug(Statin)

Study type

Interventional

Funder types

Other

Identifiers

NCT06041399
Dbinbin

Details and patient eligibility

About

The goal of this observational study is to explore the relationship between related blood indicators and diabetic peripheral neuropathy.

Full description

This is a multi-center(about five), randomized, double-blind, placebo-controlled clinical trial with over 1000 subjects.Clinical data were collected by consulting the patient's electronic history. The data included demographic information, blood biochemical markers and electromyography. All participants provided their written informed consent to participate in this study.The study protocol was approved by the Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University(KY-2022-R009).

Enrollment

1,400 estimated patients

Sex

All

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • patients who had undergone nerve conduction examination by electromyography(EMG).

Exclusion criteria

  • pregnancy and lactation; chronic liver disease, kidney disease, arrhythmias, malignant diseases, severe respiratory diseases, heart failure, and acute infections;
  • patients with alcohol abuse; history of Autoimmune liver disease, liver disease or abnormal liver function at baseline;
  • parathyroid diseases (including hyperthyroidism and hypothyroidism);
  • pancreatitis, pancreatectomy or any transplant;
  • patients with malignancy and any serious concomitant disease limit the existence of life expectancy

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

1,400 participants in 4 patient groups

diabetic peripheral neuropathy group with hypoglycemic or lipid-lowering drugs.
Experimental group
Description:
Patients with type 2 diabetic peripheral neuropathy were categorized into the diabetic peripheral neuropathy group with hypoglycemic or lipid-lowering drugs group.The group treated with specific drug,like hypoglycemic or lipid-lowering drugs.
Treatment:
Drug: lipid-lowering drug(Statin)
Drug: hypoglycemic Agents(metformin)
diabetic peripheral neuropathy group without hypoglycemic or lipid-lowering drugs.
No Intervention group
Description:
Patients with type 2 diabetic peripheral neuropathy were categorized into the diabetic peripheral neuropathy group without hypoglycemic or lipid-lowering drugs group.No hypoglycemic or lipid-lowering drugs were used in this group.
Diabetic group with hypoglycemic or lipid-lowering drugs.
Experimental group
Description:
Patients with type 2 diabetes mellitus but not with diabetic peripheral neuropathy were distributed into the Diabetic group with hypoglycemic or lipid-lowering drugs group. group.The group treated with specific drug,like hypoglycemic or lipid-lowering drugs.
Treatment:
Drug: lipid-lowering drug(Statin)
Drug: hypoglycemic Agents(metformin)
Diabetic group without hypoglycemic or lipid-lowering drugs.
No Intervention group
Description:
Patients with type 2 diabetes mellitus but not with diabetic peripheral neuropathy were distributed into the Diabetic group without hypoglycemic or lipid-lowering drugs group.No hypoglycemic or lipid-lowering drugs were used in this group.

Trial contacts and locations

1

Loading...

Central trial contact

Binbin Deng, Doctor

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems